In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS

 

The importance of shock lead positioning in patients with coronary artery disease

Session Poster session II

Speaker Tariel Atabekov

Congress : ICNC, Nuclear Cardiology & Cardiac CT 2019

  • Topic : imaging
  • Sub-topic : Single Photon Emission Computed Tomography (SPECT)
  • Session type : Poster Session
  • FP Number : P293

Authors : T Atabekov (Tomsk,RU), R Batalov (Tomsk,RU), S Krivolapov (Tomsk,RU), M Khlynin (Tomsk,RU), S Sazonova (Tomsk,RU), A Levintas (Tomsk,RU), S Popov (Tomsk,RU)

Authors:
T Atabekov1 , R Batalov1 , S Krivolapov1 , M Khlynin1 , S Sazonova1 , A Levintas1 , S Popov1 , 1State Research Institute of Cardiology of Tomsk, Heart Arrhythmyas Department - Tomsk - Russian Federation ,

Citation:

Introduction. Myocardial perfusion disorders are usually underestimated during  the defibrillation lead implantation. This may impair a proper functioning of the lead (pacing threshold, sensing and impedance) resulting in detection fails. So, it’s important to find out a new criteria that can determine the most suitable place for the lead implantation.

Aim. The defibrillation lead implantation technique optimization using cardiac scintigraphy in patients with coronary artery disease (CAD).

Material and methods. 81 patients (male - 72, age 64,0±8,7 years) with CAD and cardioverter-defibrillator (ICD) implantation indications were examined. Patients were divided into two groups. In the 1-st group before ICD implantation, patients underwent cardiac 99mTc-methoxy-isobutyl-isonitrile scintigraphy for the right ventricle wall perfusion disorders assessment (figure 1). In this group defibrillating lead was implanted to the septal position, if the perfusion disorders were in the apical segments, and to the apical position, if perfusion disorders were in the septal segments. In the 2-nd group lead was implanted using the conventional approach. Defibrillating lead parameters (pacing threshold, sensing, impedance and shock impedance on 1-st, 7-th, 30-th and 180-th follow-up days) were compared. Statistical analysis of the results was performed using the Statistica 10.0 software package. To assess the normality of the data distribution, the Kolmagorov-Smirnov test was used. The arithmetic mean (M), standard deviation (SD), median (M?) and quartiles [Q1, Q3] were calculated. The Mann-Whitney test for independent samples was used for groups comparing.

Results. The 1-st group consisted of 45 (55,5%) patients (male - 41, age 62,2±8,8 years). Perfusion disorders were diagnosed in all patients, the summed rest score was 20,00% [13,00; 32,00]. For 28 (62,2%) patients ICD was implanted for primary, and 17 (37,8%) - for the secondary sudden cardiac death prevention. In 28 (62,2%) cases in this group defibrillating lead was implanted to the apical and in 17 (37,8%) - to the septal position.

The 2-nd group consisted of 36 (44,5%) patients (male - 31, age 66,3±8,2 years (p=0,03)). For 21 (58,3%) patient ICD was implanted for primary, and 15 (41,7%) - for the secondary sudden cardiac death prevention. In 20 (55,5%) cases in this group defibrillating lead was implanted to the septal and in 16 (44,5%) - to the apical position.

There were significant differences between groups in terms of: threshold and sense at all follow-up days (p=0,0001) and impedance on 1-st (p=0,003), 30-th (p=0,0001) and 180-th day (p=0,002), respectively. Conclusion. Assessment of the right ventricular perfusion before ICD implantation can reduce the pacing threshold and raise sensing, thereby prolong the ICD longevity and improve life-threatening ventricular tachyarrhythmias detection in the early and long-term period in patients with CAD.

This content is currently on FREE ACCESS

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are